May 30, 2014 · Merck (NYSE: MRK), known as MSD outside the United States and Canada, today said that the nonproprietary name for MK-3475, Merck’s investigational anti-PD-1 …

Nov 19, 2024 · Investigational subcutaneous pembrolizumab and berahyaluronidase alfa, in combination with chemotherapy, demonstrates noninferior pharmacokinetics compared to …

Nov 11, 2012 · About PD-1 and MK-3475. Research has shown that PD-1, an immune checkpoint receptor, helps to confer immune resistance for some cancers allowing tumor cells to grow …

Oct 1, 2015 · Purpose: This phase I study evaluated the safety, maximum tolerated dose, antitumor activity, and pharmacokinetics and pharmacodynamics of pembrolizumab in patients …

Sep 30, 2015 · Pembrolizumab (MK-3475) is a potent, highly selective, IgG4-κ humanized monoclonal antibody that prevents PD-1 binding with its ligands, PD-L1 and PD-L2. This report …

A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or …

Trial P001 is a multicenter, international, open-label, multi-cohort study of MK-3475 in patients with advanced melanoma and carcinoma.

This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy (NAC) before surgery [neoadjuvant phase], …

In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab …

May 14, 2014 · Six oral presentations report MK-3475 monotherapy data across three different tumor types and multiple lines of therapy ; Late-breaker presentation of long-term findings of …